Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Neuphoria Therapeutics (NEUP) Net Margin (2024 - 2025)

Neuphoria Therapeutics (NEUP) has disclosed Net Margin for 1 consecutive years, with 114247.12% as the latest value for Q2 2025.

  • On a quarterly basis, Net Margin changed N/A to 114247.12% in Q2 2025 year-over-year; TTM through Dec 2025 was 79.65%, a N/A change, with the full-year FY2025 number at 42.45%, changed N/A from a year prior.
  • Net Margin was 114247.12% for Q2 2025 at Neuphoria Therapeutics, up from 75.08% in the prior quarter.
  • In the past five years, Net Margin ranged from a high of 114247.12% in Q2 2025 to a low of 75.08% in Q1 2025.